Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

Role of PCSK9 Inhibitors in Diabetes

Stephen Kopecky

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

National Lipid Association

R. Mason

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

Colchicine: Now and What’s Next?

National Lipid Association

C. Ballantyne

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Practical Ways to Achieve Targets in Diabetes Care

S. Nissen

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

New Therapeutic Options for the Management of the Hospitalized Patie…

28th Annual Heart Failure 2024: An Update on Therapy

U. Elkayam

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Plant-based Diets for Improving Lipids

National Lipid Association

K. Williams

Role of Lipoprotein (a) in Coronary Disease: An Emerging Novel Target

Practical Ways to Achieve Targets in Diabetes Care

S. Nissen

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin